Vitaliy Duvalko

Building the world’s best bioprinter.
@Adam_Biotech

[Vitaliy Duvalko @vitalduval]

Preclinical evaluation isn’t ready for the AI drug boom.

We design drugs faster than we can test them. 90% entering clinical trials still fail, even after promising preclinical results.

We’re fixing that: 3D-bioprinted human tissues, on demand, built to de-risk your drug.

[Vitaliy Duvalko @vitalduval]

@nisargxj @NatalieLeviii @obotiq Very very cool

[Vitaliy Duvalko @vitalduval]

@daleverett Wow crazy.

[Vitaliy Duvalko @vitalduval]

@humfhuang We should meet up

[Vitaliy Duvalko @vitalduval]

Preclinical evaluation isn’t ready for the AI drug boom.

We design drugs faster than we can test them. 90% entering clinical trials still fail, even after promising preclinical results.

We’re fixing that: 3D-bioprinted human tissues, on demand, built to de-risk your drug.

[Vitaliy Duvalko @vitalduval]

@parmita Let’s connect. Are you in the bay?

[Vitaliy Duvalko @vitalduval]

@BrunoMenarim True

[Vitaliy Duvalko @vitalduval]

Preclinical evaluation isn’t ready for the AI drug boom.

We design drugs faster than we can test them. 90% entering clinical trials still fail, even after promising preclinical results.

We’re fixing that: 3D-bioprinted human tissues, on demand, built to de-risk your drug.

[Vitaliy Duvalko @vitalduval]

@ahengyuc World changing.

[Vitaliy Duvalko @vitalduval]

https://t.co/eW5VWwQyO1

[Vitaliy Duvalko @vitalduval]

@AnselDias @fdotinc @heyato_ai It’s been great seeing the progress here.

[Vitaliy Duvalko @vitalduval]

@humfhuang 🔥

[Vitaliy Duvalko @vitalduval]

@ahengyuc @Adam_Biotech 10/10

[Vitaliy Duvalko @vitalduval]

Coming soon…
@Adam_Biotech

[Vitaliy Duvalko @vitalduval]

@jainavx @nashpateee Founder moment

[Vitaliy Duvalko @vitalduval]

@MenarimBruno Yes, definitely reaches past just brain organoids.

[Vitaliy Duvalko @vitalduval]

Brain computing through organoids has a fundamental problem:

Past a certain size, organoids develop a necrotic core where nutrients can’t diffuse into the center. So the cells die.

They’ve tried to fix this by adding blood vessels inside the brain organoid. But these are self-assembling - you can’t place them in specific locations.

So bioprinting is a much more promising solution - Print brain tissue and vascular networks at the same time. The brain tissue can be far larger, be made much faster, and you have control over the placement of each blood vessel and neuron cluster.

[Jarvis Nuss @jarvisnuss]

Brain organoid computing still sits at the awkward stage where the demos sound like theater and the bottleneck is real enough to be interesting. The JMIR piece on biocomputing names the serious detail. Cortical Labs and FinalSpark are wiring small neural organoids onto multi-electrode arrays, then letting remote researchers stress the tissue with signals, drugs, and feedback loops.

The useful scandal is energy. Silicon scales by making computation cleaner, faster, and more predictable. Biology got good at a different game, learning from noisy scraps while burning almost nothing. If organoid systems remain chaotic, fragile, and ethically annoying, that still does not make them toys. It makes them instruments for discovering what computation looks like before engineering domesticates it.

The correct posture is neither reverence nor panic. Put the tissue on the bench, measure it hard, price the constraints, and let the results embarrass both mystics and regulators.

[Vitaliy Duvalko @vitalduval]

@jarvisnuss Right! The process is much more controllable than growing organoids.

[Vitaliy Duvalko @vitalduval]

@ahengyuc I can attest to the 50h.

[Vitaliy Duvalko @vitalduval]

Exactly. I see a vision where:

1) AI creates a new drug

2) AI identifies the key risks of that drug. Maybe it’s an immune reaction or endocrine

3) AI designs the optimal tests to mitigate these key risks. Perhaps it’s organ-on-a-chip with specific cell concentrations generated by AI, or a bunch of bioprints with each one designed to test some key risk

[Parmita Mishra @parmita]

the future of medicine will not be won by the company with the loudest model
it will be won by the company with the best biological feedback loop

@precigenetics